-

Flatiron Health Embarks on Strategic Collaboration with Sanofi to Make Clinical Trials More Efficient by Streamlining Data Acquisition at the Point of Care

One of the industry’s first scalable EHR-to-EDC technologies that enables sites to transfer data more efficiently, resulting in faster access to cleaner data with less burden for both sites and sponsors

NEW YORK--(BUSINESS WIRE)--Flatiron Health announced a new collaboration today with Sanofi in their pursuit to redesign the clinical trial experience for sponsors, sites, and patients in the therapeutic area of oncology.

The multi-study collaboration between Sanofi and Flatiron will focus on improving clinical trial data acquisition, delivery, and quality through site-facing technology that digitally transfers data captured in the electronic health record (EHR) directly into the electronic data capture (EDC) system through Flatiron Health’s EHR-to-EDC product, Flatiron Clinical Pipe™. Clinical trial sites will be able to reduce time spent on both manual, high-volume data entry and downstream data resolution issues, so that they have more time to spend with patients.

By focusing on the area of oncology, this collaboration intends to accelerate development of new treatments and help more people with cancer. The collaboration will make it easier for sites to participate in oncology trials by reducing redundant, manual and often error-prone data entry processes, including taxing local lab management. This novel approach will be used across a portfolio of trials and a broad network of research sites - including both Academic and Community cancer centers.

The initial Sanofi trial using Flatiron’s technology had its first automated data push earlier this year, successfully transferring over 50% of study data1 from the EHR to the EDC. Sanofi and Flatiron will collaborate on data standards and mapping to expand the volume and types of data eligible for automated transfer. Additionally, as a result of deploying Flatiron Clinical Pipe™, Flatiron expects the number of queries to decrease by roughly 50%, adding to efficiency gains for both sites and Sanofi study teams2.

“Flatiron’s expansion into the clinical research space is a natural progression for us. With the FDA’s guidance3 on interoperable technology that allows electronic transmission of relevant EHR data to the EDC system, we knew we had an opportunity with Flatiron Clinical Pipe to unlock the potential of data captured in the EHR, reduce the burden of clinical trials and accelerate research timelines,” says Alex Deyle, General Manager, Clinical Research, Flatiron Health. “We’re incredibly excited to collaborate and partner with forward-thinkers like Sanofi, who share our aspiration to leverage data and technology to transform clinical research. We look forward to working with the industry to solve a variety of challenges in the clinical research space—for the benefit of sponsors, CROs, sites and ultimately, the patients.”

About Flatiron Health

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth

About Flatiron Clinical Pipe™

Flatiron Clinical Pipe™ is one of the industry’s first scalable EHR-to-EDC connectors that enables data transfer between most major EHR and EDC systems. Flatiron Clinical Pipe™ eliminates double data entry, allowing health care providers and research staff to spend more time focusing on patients.

References

  1. Sanofi data, February 2023
  2. Sanofi data, 2022
  3. FDA.gov. Use of Electronic Health Record Data in Clinical Investigations. FDA Guidance for Industry. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH). July 2018. https://www.fda.gov/media/97567/download

 

Contacts

Media

Flatiron Health
Nina Toor
communications@flatiron.com

Flatiron Health

Details
Headquarters: New York, NY
CEO: Carolyn Starrett
Employees: 2,500
Organization: PRI

Release Versions

Contacts

Media

Flatiron Health
Nina Toor
communications@flatiron.com

More News From Flatiron Health

Flatiron Health Announces 18 Research Acceptances Featuring Flatiron's Real-World Data to Be Presented at ISPOR 2026

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the ISPOR—The Professional Society for Health Economics and Outcomes Research Annual Meeting happening from May 17-20, 2026, in Philadelphia, Pennsylvania. Flatiron's high-quality real-world data and innovative research capabilities are featured across 18+ research acceptances, including seven Flatiron authored research posters as well as a panel presentation “Beyond Black Boxes: Transparent, Validated LLM Workflows for...

Flatiron Health Publishes First Peer-Reviewed Validation Framework for AI-Extracted Real-World Oncology Data in Journal of Clinical Oncology

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced the publication of the Validation of Accuracy for LLM/ML-Extracted Information and Data (VALID) Framework in the Journal of Clinical Oncology Clinical Cancer Informatics. The framework represents the first and most comprehensive, peer-reviewed approach to evaluating the quality and reliability of real-world data extracted by large language models (LLMs) and machine learning—setting a methodological benchmark for data integrity in oncolo...

Flatiron Health Attends the 2026 American Society of Genitourinary Cancers Symposium to Answer Oncology's Most Critical Questions

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the American Society of Genitourinary Cancers Symposium happening from February 26-28, 2026, in San Francisco, California. Flatiron's real-world data and research capabilities are featured across multiple presentations, including 6 research acceptances spanning genitourinary cancers. A cornerstone of Flatiron’s presence at ASCO GU 2026 is the global prostate cancer and bladder cancer Panoramic datasets, which draw from o...
Back to Newsroom